

Short Review

Radioactive Ablation Therapy: Precision Radiation for Targeted Destruction of Diseased Tissue

Schlessinger D, Ghossein E, Carvalho F, Baudin W, Travagli A

Department of Internal Medicine, Iran

***Corresponding Author:** Ghossein E, Department of Internal Medicine, Iran

Citation: Ghossein E (2026). Radioactive Ablation Therapy: Precision Radiation for Targeted Destruction of Diseased Tissue V2(2)

Copyright: © 2026 Ghossein E, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received date: August 29, 2026: **Accepted date:** September 19, 2026: **Published date:** September 28, 2026

Keywords: radioactive ablation, radionuclide therapy, radioiodine therapy, targeted radiotherapy, nuclear medicine, radiopharmaceuticals, molecular imaging, cancer therapy

Abstract

Radioactive ablation therapy is a targeted therapeutic approach that uses ionizing radiation delivered through selected radionuclides to destroy abnormal or diseased tissue while attempting to minimize injury to surrounding healthy structures. Unlike conventional external-beam radiation, radioactive ablation can exploit the biological or physiological characteristics of specific tissues to concentrate radiation within a therapeutic target. The best-established applications include radioiodine therapy for differentiated thyroid disorders and radionuclide-based treatment of selected malignant and non-malignant conditions. More recently, advances in nuclear medicine have expanded the concept toward targeted radionuclide therapy, in which radiopharmaceuticals bind to specific molecular or cellular targets and deliver cytotoxic radiation directly to diseased tissue. The therapeutic effects primarily arise from radiation-induced DNA damage, cellular apoptosis, and loss of reproductive capacity. Treatment selection depends on disease biology, radionuclide characteristics, target expression, tumor burden, organ function, and patient-specific risk factors.

Introduction

Radioactive ablation therapy represents an important intersection between nuclear medicine, radiation oncology, and precision medicine. The fundamental concept is to use radioactive substances to deliver therapeutic radiation to abnormal tissue. Depending on the clinical indication, the radionuclide may be administered systemically, taken up physiologically by a particular tissue, or attached to a carrier molecule that recognizes a specific cellular target.

The approach differs from conventional radiation therapy because the radioactive agent itself acts as the source of radiation. This enables treatment of selected tissues from within the body and, in some circumstances, permits radiation to reach microscopic or disseminated disease that may not be easily addressed by local procedures.

Biological Basis of Radioactive Ablation

The therapeutic effect of radioactive ablation is primarily mediated by ionizing radiation. When emitted radiation interacts with cellular structures, it can directly damage DNA or indirectly generate reactive chemical species that produce DNA injury.

Double-stranded DNA damage is particularly important because extensive or irreparable damage can prevent cellular replication and ultimately lead to cell death. The therapeutic response depends on several factors, including

- Type and energy of radiation emitted
- Physical half-life of the radionuclide
- Biological half-life within the target tissue
- Amount of radioactivity administered
- Distribution of the radiopharmaceutical
- Radiosensitivity of the target cells
- Ability of surrounding tissues to repair radiation injury

Alpha- and beta-particle emitters are particularly important in therapeutic nuclear medicine. Beta particles can travel several millimeters through tissue,

Journal of Endocrinology, Diabetes and Metabolic Complications (JEDMC)

whereas alpha particles have a much shorter range but produce highly dense ionization along their path. This difference influences which radionuclide is appropriate for a particular clinical application.

Radioiodine Therapy

Radioiodine therapy is the classic example of radioactive ablation. I-131 is a radioactive form of iodine that can be selectively concentrated by thyroid tissue through the sodium-iodide symporter.

Following administration, radioactive iodine accumulates in iodine-avid thyroid cells. Beta radiation emitted by I-131 produces local tissue destruction, while its gamma emissions can also permit imaging and monitoring.

Radioiodine therapy has important applications in:

- Hyperthyroidism
- Selected differentiated thyroid cancers
- Ablation of residual thyroid tissue after surgery in appropriately selected patients
- Treatment of iodine-avid metastatic thyroid disease

The effectiveness of treatment depends on iodine uptake, disease burden, patient preparation, and appropriate activity selection.

Targeted Radionuclide Therapy

The field has progressed from tissue-specific radioiodine treatment toward molecularly targeted radionuclide therapy. In this approach, a radionuclide is linked to a ligand, peptide, antibody, or other carrier that recognizes a molecular target expressed by diseased cells

This strategy has been explored and clinically implemented in selected malignancies involving targets such as:

- Somatostatin receptors
- Prostate-specific membrane antigen (PSMA)
- Other tumor-associated molecular targets

Mechanism of Tissue Destruction

After the radiopharmaceutical reaches the target, emitted radiation deposits energy within or around the diseased cells. This may produce:

1. DNA strand breaks
2. Oxidative stress
3. Chromosomal damage

4. Cell-cycle arrest
5. Apoptosis or other forms of cell death
6. Loss of cellular reproductive capacity

Patient Selection and Treatment Planning

Appropriate patient selection is essential for achieving a favorable therapeutic ratio. Evaluation may include:

- Confirmation of the diagnosis
- Assessment of disease extent
- Evaluation of target expression or radiopharmaceutical uptake
- Renal and hepatic function assessment where relevant
- Hematologic evaluation
- Pregnancy and breastfeeding assessment when applicable
- Review of previous radiation or systemic treatments
- Evaluation of factors that may increase radiation toxicity

Radiation Safety

Radiation safety is a fundamental component of radionuclide therapy. Depending on the radionuclide and administered activity, patients may temporarily emit radiation and excrete radioactive material through biological fluids.

Specialized treatment protocols may therefore include:

- Radiation-protection instructions
- Appropriate handling of bodily fluids
- Temporary restrictions on close contact
- Special precautions for children and pregnant individuals
- Monitoring of radiation exposure where clinically required

Conclusion

Radioactive ablation therapy has evolved from established tissue-specific applications such as radioiodine treatment into a broader platform for targeted radionuclide therapy. By delivering ionizing radiation directly to selected tissues or molecular targets, this approach can provide effective treatment for appropriately selected patients, including individuals with certain metastatic diseases.


References

1. Calegari JU, De Freitas Gomes E, Bae SH, Ulyssea R, Casulari LA (2000) One-year follow-up of Graves' disease treatment by four different

Journal of Endocrinology, Diabetes and Metabolic Complications (JEDMC)

- protocols of radioiodine administration. *Panminerva Med.* 42(4):241 –245
2. Traino AC, Grosso M, Mariani G (2010) Possibility of limiting the un-justified irradiation in (131) I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation. *Phys Med.* 26(2):71 –79.
 3. Accardo, G.; Conzo, G.; Esposito, D.; Gambardella, C.; Mazzella, M.; Castaldo, F.; Di Donna, C.; Polistena, A.; Avenia, N.; Colantuoni, V.; et al. Genetics of medullary thyroid cancer: An overview. *Int. J. Surg.* 2017, 41 (Suppl. S1), S2–S6.
 4. Campennì, A.; Giovanella, L.; Pignata, S.A.; Vento, A.; Alibrandi, A.; Sturiale, L.; Laudicella, R.; Comis, A.D.; Filice, R.; Giuffrida, G. Undetectable or low (<1 ng/mL) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients. *Oncotarget* 2018, 9, 17491.

Journal of Endocrinology, Diabetes and Metabolic Complications (JEDMC)



This work is licensed under Creative Commons Attribution 4.0 License
DOI:10/JEDMC/2026/020

Your next submission with**Olites Publishers will reach you the below assets**

- We follow principles of publication led by the Committee on Publication Ethics (COPE).
- Double-blind peer review process which is just as well as constructive.
- Permanent archiving of your article on our website
- Quality Editorial service
- Manuscript accessibility in different formats (PDF, Full Text)
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

Learn more: [Journal of Endocrinology, Diabetes and Metabolic Complications – Olites Publishers \(olitespublishing.com\)](https://olitespublishing.com/)